Introduction: Biliary tract cancer (BTC) is an uncommon tumor with bad prognosis. There is no curative treatment for patients with unresectable disease at diagnosis. There is a limited experience with second-line chemotherapy in advanced BTC since clinical trials are difficult to perform due to the rarity and heterogeneity of these tumors.
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The patient presented grade 4 afebrile neutropenia, grade 1 anemia and grade 3 renal failure as main treatment toxicities. For this reason, after 6 cycles of chemotherapy with maintained PR, we decided to continue with gemcitabine monotherapy. After 3 cycles of treatment in September 2017, the CT scan revealed disease progression, with an increase of the infundibulum tumor volume ( Figure 1F ). At this point, the patient had recovered from the previous treatment toxicities and maintained an excellent general status, so we started second-line chemotherapy treatment with capecitabine and oxaliplatin combination. A new CT scan was performed in December 2017 after receiving 3 cycles of treatment, which showed disappearance of the tumor lesion. The CR was also confirmed with Hepatic magnetic resonance imaging (MRI) ( Figure 3 ). As an incidental finding, a mold of biliary mud with retrograde secondary dilation of the hepatic common duct was seen.
An Endoscopic retrograde cholangiopancreatography (ERCP) with direct cholangioscopy was then performed, confirming the absence of the tumor and the existence of the lithiasic mold which was partially removed. The biliary stent was changed and another ERCP was programed for complete stone removal. Given the accumulative hematological toxicity and the absence of disease in the imaging tests, we decided to stop chemotherapy treatment in Chemotherapy has been commonly used to improve the outcome of these patients and to delay tumor progression. [8, 9] .
In other study, 56 patients diagnosed with BTC (36 cholangiocarcinoma and 20 gallbladder cancer) received the combination of capecitabine and oxaliplatin. In a preliminary report, two complete and seven partial responses were observed, and a great proportion of patients experienced prolonged periods of stable disease [10] . The unusual good response to chemotherapy of our case is worth reporting, especially because systemic chemotherapy is considered little effective in disseminated or unresectable cholangiocarcinoma and there is still no established protocol in the second-line setting. Previous studies have reported isolated cases of pathological complete response (pCR) to chemotherapy in advanced BTC. In a single center phase II study that evaluated the combination chemotherapy of (GEMOX) for advanced Gallbladder cancer patients, Sharma et al. reported one case of pCR [11] . Another case report also showed a pCR in a patient with BTC after five courses of the GEMOX regimen [12] . Walker et al. regimen [13] . Other authors have also described cases of pCR in advanced disease with the combination chemotherapy of gemcitabine and S-1 [14, 15] and gemcitabine-cisplatin-S1 [16] (Table 1) . Recent molecular studies have increased our understanding of pathogenetic mechanism that underly the development of cholangiocarcinoma. These have helped us to determine the significance of molecular alterations that occur in this disease and will direct the development of targeted therapy. Different studies have revealed that BTC develops in the context of chronic inflammation and cholestasis [17] . In these studies cholangiocarcinogenesis is associated with proinflammatory cytokines such as interleukin-6 (IL-6) [18] . BTC cells synthesize and secrete IL-6, with subsequent auto-and paracrine stimulation of the IL-6 receptor. Negative feedback mechanisms regulating IL-6 signaling are frequently inactivated in these tumor cells. Activation of the IL-6 receptor results in activation of
